Skip to main content

The Evolution of Myopia

Your Results

At -/ years old:

-/ diopter -/ diopter

Ocular axial length will increase with:

-/ mm -/ mm

Patient’s ocular axial length:

-/ mm -/ mm

At -/ years old:

-/ diopter -/ diopter

Ocular axial length will increase with:

-/ mm -/ mm

Patient’s ocular axial length:

-/ mm -/ mm

At -/ years old:

-/ diopter -/ diopter

Ocular axial length will increase with:

-/ mm -/ mm

Patient’s ocular axial length:

-/ mm -/ mm

Percentage reduction of Myopia Progresion

Percentage reduction of Myopia Proresion with the application of the selected treatment compared to monofocal optical correction

At -/ years old:

-/ %

At -/ years old:

-/ %

At -/ years old:

-/ %

About

The “Myopia Calculator” is a program that allows the user to be informed about the progression of the patient’s myopia depending on the selected treatment, the degree of myopia, age, the initial annual progression of myopia and the presence or absence of the family factor.
“Myopia Calculator” is a tool that helps ophthalmologists, doctors, and patients parents to apply data based on scientific research to analyze various options management and allows the doctor to demonstrate and discuss the “risk / benefit” aspects for each individual case.
The “Myopia Calculator” can be used to estimate the annual evolution of myopia, showing the refractive error (D) and the ocular axial length (mm) which will result in application or denial of myopia treatment. This is calculated using the following patient information:

  • Management of myopia.
  • Dioptric value (diopters).
  • Ocular axial length (millimeters).
  • Age.
  • Annual gradient of progression of myopia (diopters / year).
  • The family factor.

Using “estimated annual progression without management (treatment)” as a method reference, the computer can be used to determine the extent of the progression annual can be reduced with a myopia management scenario.

Scientific base

The estimated annual progression of myopia is calculated using the calculation methodology from doctoral thesis in medical sciences from 2016 of P.h.D. MD Rodica Bilba with the theme “The effectiveness of treatment and prophylaxis in managing the progression of uncomplicated acquired myopia.” The materials presented in thesis are the result of their own research and scientific achievements and are patented:

1. Patent inventor at the State Intellectual Property Agency of the Republic of Moldova with Number: 39 MD 39 Z A61F 9/00, A61B 18/12, A61N 5/067, A61H 5/00, A61H 39/00. “Method of treatment for uncomplicated progressive acquired myopia.”. Bîlba Rodica, Ghidirimschi Tatiana, Bendelic Eugen. Application submitted 30.06.2009, BOPI nr. 6/2009..

2. Patent of invention no. 1639, MD 1639 Z A61B 3/00, A61B 10/00. Prognosis method of the evolution of myopia according to the annual progression gradient in children. Bîlba Rodica, Necula Gheorghe. Application submitted 31.08.2022, BOPI no. 8/2022.

3. Patent of invention no. 1640, MD 1640 Z A61B 3/00, A61B 10/00. Prognosis method of the evolution of myopia according to the annual progression gradient. Bîlba Rodica, Necula Gheorghe. Application submitted 31.08.2022, BOPI no. 8/2022.

How it works

The application presents the different management options / scenarios and the possible results for three years. As an indication for the use of this method is the information and warning of patients with uncomplicated acquired myopia of small and medium degree about the evolution of myopia without treatment, as well as about the objective results, based on scientific data, of each proposed treatment method.

After entering the required data, the program performs calculations according to the algorithm developed and presents data on the annual evolution of myopia according to the spheroequivalent (in diopters) and the ocular axial length (in millimeters). These data are also presented for an annual period of three consecutive years from the user’s current age.

The results of the calculations are presented depending on the treatment method initially chosen compared to the application of monofocal optical correction. Also, the data are presented in both values absolute as well as percentage, numerically and graphically.

Medical disclaimer

This “Myopia Calculator” provides information only and should not be considered as medical or treatment advice. Users should not rely on it for medical diagnosis or treatment recommendations. The information on this program is not a substitute for professional medical advice, diagnosis, or treatment. All content, including text, video, images, and information, available through this program, is for general informational purposes only. Users are strongly encouraged to consult with their physician or another professional healthcare provider for confirmation and review of any medical condition or treatment information obtained from or through this program.

YOU SHOULD NEVER BASE ANY DIAGNOSIS OR MEDICAL TREATMENT RECOMMENDATION ON INFORMATION OBTAINED USING THIS PROGRAM. YOU SHOULD NEVER SUBSTITUTE PROFESSIONAL MEDICAL ADVICE FROM YOUR PHYSICIAN OR ANOTHER PROFESSIONAL HEALTHCARE PROVIDER WITH INFORMATION RECEIVED FROM THIS PROGRAM. YOU SHOULD NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BASED ON ANY INFORMATION YOU HAVE SEEN ON OR ACCESSED THROUGH THIS PROGRAM. IF YOU HAVE SPECIFIC QUESTIONS ABOUT ANY MEDICAL ISSUE, YOU SHOULD CONSULT YOUR PHYSICIAN OR ANOTHER PROFESSIONAL HEALTHCARE PROVIDER. IF YOU BELIEVE YOU ARE EXPERIENCING ANY MEDICAL CONDITION, YOU SHOULD SEEK IMMEDIATE MEDICAL ATTENTION.

The information provided by this program is provided “as is” without any representations or warranties, express or implied. Myopia Calculator makes no representations or warranties regarding the medical or other information in this program.

MYOPIA CALCULATOR IS NOT RESPONSIBLE OR LIABLE FOR ANY ADVICE, TREATMENT COURSE, DIAGNOSIS, OR ANY OTHER INFORMATION, SERVICES, OR PRODUCTS OBTAINED THROUGH THE USE OF THIS PROGRAM.

The estimated annual progression is calculated using data from the PhD thesis of PhD MD Rodica Bilba with the theme “THE EFFECTIVENESS OF TREATMENT AND PROPHYLAXIS IN MANAGING THE PROGRESSION OF UNCOMPLICATED ACQUIRED MYOPIA.”

The materials presented in the thesis are the result of their own research and scientific achievements and are patented by the Inventor Patents at the State Agency of Intellectual Property of the Republic of Moldova, number:

1. 39 MD 39 Z A61F 9/00, A61B 18/12, A61N 5/067, A61H 5/00, A61H 39/00. “Method of treatment for uncomplicated progressive acquired myopia.”. Bîlba Rodica, Ghidirimschi Tatiana, Bendelic Eugen. Application submitted 30.06.2009, BOPI nr. 6/2009.
2. Patent of invention no. 1639, MD 1639 Z A61B 3/00, A61B 10/00. Prognosis method of the evolution of myopia according to the annual progression gradient in children. Bîlba Rodica, Necula Gheorghe. Application submitted 31.08.2022, BOPI no. 8/2022.
3. Patent of invention no. 1640, MD 1640 Z A61B 3/00, A61B 10/00. Prognosis method of the evolution of myopia according to the annual progression gradient. Bîlba Rodica, Necula Gheorghe. Application submitted 31.08.2022, BOPI no. 8/2022.

For advice and treatment of myopia, users should always consult an expert eye care practitioner who can perform necessary tests and provide appropriate advice. With ongoing research on myopia management, we do not guarantee the accuracy or applicability of the information currently provided on the site for future use. The Myopia Calculator program should be considered informational and does not constitute advice. Users should consult a relevant eye care practitioner if they have any concerns about their eye or general health as a result of content or use of this program. Myopia Calculator makes no warranties or representations, express or implied, regarding the accuracy, completeness, timeliness, or usefulness of the information contained or referenced in this program. Myopia Calculator assumes no risk for the individual user and/or the healthcare professional’s use of the information contained herein.

This information is provided for general informational purposes only and does not constitute advice.